Icatibant, an antagonist of bradykinin B2 receptors approved for treating HAE, has shown promise in ACE inhibitor-induced AE based on case reports indicating significant symptom resolution upon its administration in ACE inhibitor-induced AE cases [65,66]. Here, ACE is linked to hereditary angioedema.